| [1] |
YIN Xiaoyu, DONG Liping, XIAO Fengli, .
Upadacitinib for ankylosing spondylitis complicated with secukinumab-associated atopic dermatitis: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2026, 42(9): 656-659.
|
| [2] |
PU Qianhan, ZHENG Chen, ZOU Ailing.
Dupilumab for the treatment of atopic dermatitis complicated with twenty-nail dystrophy: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2026, 42(8): 599-601.
|
| [3] |
GAO Mingxuan, WU Juan, WANG Yang, ZHAO Jiahui.
Research progress on CARD11 mutations and regulatory T cell dysfunction in atopic dermatitis
[J]. China Journal of Leprosy and Skin Diseases, 2026, 42(7): 536-541.
|
| [4] |
WU Mengwei, LIU Peize, LI Haoyuan, CHEN Hanxiang, ZHI Lili.
Dupilumab-associated ocular surface disease complicated with HSV-1 and Staphylococcus aureus infection: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2026, 42(6): 450-452.
|
| [5] |
MEI Yajie, SU Fei, CHEN Hui, JIANG Min.
Real-world efficacy and safety of abrocitinib in elderly patients with moderate-to-severe atopic dermatitis
[J]. China Journal of Leprosy and Skin Diseases, 2026, 42(5): 344-347.
|
| [6] |
WAN Guijun, LI Jingyi.
Role of transient receptor potential channels in the pruritus of atopic dermatitis
[J]. China Journal of Leprosy and Skin Diseases, 2026, 42(5): 382-388.
|
| [7] |
XIA Pu, MO Ran, CHEN Zhiming, YANG Yong.
A case of atopic dermatitis associated with CARD11 variant
[J]. China Journal of Leprosy and Skin Diseases, 2026, 42(3): 152-157.
|
| [8] |
SHAO Yuling, WANG Na.
Successful treatment of dupilumab-associated nail psoriasis with upadacitinib: a case report and literature review
[J]. China Journal of Leprosy and Skin Diseases, 2026, 42(3): 206-210.
|
| [9] |
BI Zhixia, HAN Jindou.
Dupilumab versus abrocitinib in the treatment of atopic dermatitis: a meta-analysis of efficacy and safety
[J]. China Journal of Leprosy and Skin Diseases, 2026, 42(1): 5-10.
|
| [10] |
BAI Fan, YU Wanlong, XU Yabo, FAN Lifang, LIU Yuyuan, TIAN Zan, LEI Mingjun.
Efficacy of abrocitinib in the treatment of moderate-to-severe prurigo phenotype atopic dermatitis
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(8): 593-597.
|
| [11] |
SUN Yaru, ZHANG Yisheng, CHEN Yao, CHEN Jinbo, CHEN Liuqing.
Identification of novel therapeutic targets for atopic dermatitis based on genome-wide associationstudies and proteomic colocalization analysis
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(12): 869-875.
|
| [12] |
LU Yanfang, BAI Hui, SHI Chunrui.
Current situation of atopic dermatitis diagnosis and treatment in Gansu Province
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(12): 876-881.
|
| [13] |
CHEN Yubao, ZHANG Tao, YIN Dong, REN Shangli.
Efficacy of tripterygium glycosides wilfordii combined with dupilumab in the treatment of atopic dermatitis
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(11): 797-800.
|
| [14] |
WEI Yanjie, REN Rujiao, ZHANG Lu, ZHANG Peilian.
Dupilumab in the treatment of atopic dermatitis complicated by keloid: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(11): 821-823.
|
| [15] |
JIN Lanyan, TANG Xinyun, ZHOU Peimei.
Research advance on the oral microenvironment of atopic dermatitis based on multi-omics technology
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(11): 836-840.
|